News

A primary end point has been met in the phase 3 CONTACT-02 clinical trial.

In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.

A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.

Treatment with liso-cel had a manageable safety profile with no new safety signals in patients with relapsed/ refractory follicular lymphoma.

According to investigators of the phase 3 COLUMBUS study, BRAF/MEK inhibitor combinations are better with more BRAF inhibition.

Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.

Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.

According to Eric Jonasch, MD, promising findings from LITESPARK-005 may help with a goal of getting belzutifan FDA approval for patients with refractory renal cell carcinoma.

In an interview, Shilpa Gupta, MD, discussed findings from cohort A of Study EV-103 in patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.

For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.

Data from HER2CLIMB-02 will be presented at an upcoming medical meeting and the results will be shared with the FDA.

Guillermo Garcia-Manero, MD, discussed 2 studies evaluating therapies for patients with lower-risk myelodysplastic syndrome.

In an 8-year follow up analysis of patients on the ExteNET trial, researchers saw that overall survival was not significantly different to rates on placebo.

Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.

Several immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.

Daniel P. Petrylak, MD, highlights data from the phase 3 KEYNOTE-921 of pembrolizumab in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer.

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.

The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.

According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.

Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.

During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.

In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

Based on the largest clinical trial of patients with HER2-amplified biliary tract cancer, a novel anti-HER bispecific antibody may be the next option.